Adoptive Transfer of iNKT Cells for Treating Patients With Relapsed/Advanced HCC
Status:
Unknown status
Trial end date:
2019-03-30
Target enrollment:
Participant gender:
Summary
This study enrolls patients who have relapsed/advanced hepatocellular carcinoma (HCC, BCLC
stage C). The HCC tumor relapsed or metastasized through the body after standard treatment or
the patients cannot receive standard treatment under current conditions. This research study
uses special immune system cells called iNKT cells, a new experimental treatment.
The purpose of this study is to find the biggest dose of iNKT cells that is safe and
tolerance, to see how long they last in the body, to learn the immunoresponse in the body, to
learn the side effects are and to see if the iNKT cells will help people with
relapsed/advanced hepatocellular carcinoma (HCC).